We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App





Chembio Launches Rapid POC Test for Detecting COVID-19 Antigens, Flu A/B from Single Patient Sample in 15 Minutes

By LabMedica International staff writers
Posted on 07 Apr 2021
Print article
Illustration: Rapid POC Test for Detecting COVID-19 Antigens, Flu A/B (Photo courtesy of Chembio Diagnostic Systems, Inc.)
Illustration: Rapid POC Test for Detecting COVID-19 Antigens, Flu A/B (Photo courtesy of Chembio Diagnostic Systems, Inc.)
Chembio Diagnostic Systems, Inc. (Medford, NY, USA) has commercially launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test, for use in decentralized and traditional testing settings.

The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.

“As COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources,” said Charles Caso, Vice President of Sales and Marketing for Chembio. “Based on recent research, we expect that the spread of COVID-19 will eventually transition from a pandemic to an endemic state, with the virus surviving among the population at a lower incidence. In this scenario, coupled with the return to normalcy in society, we see COVID-19 testing remaining a crucial and integral component of broader respiratory testing.”

New
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
New
Gold Supplier
SARS-CoV-2 Antibody Test
SARS-CoV-2 UTAB FS
New
Gold Supplier
Tumor Marker Control
Tumor Marker Control
New
Silver Supplier
Nucleic Acid Extractor
Pre-NAT II

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.